Compass Group PLC Sponsored ADR (CMPGY)
Compass: Highly Profitable And Worth Buying
Compass (COMP) remains a buy as it outpaces industry growth and leverages the Anywhere Real Estate acquisition. COMP trades at a de-risked entry point, with a 10.3x EV/FY26 adjusted EBITDA multiple and strong margin improvement prospects. Q1 revenue guidance of $2.55–$2.75B implies 88–102% y/y growth, driven by M&A and expanding post-transaction services.
MSCI Acquires Compass Financial to Expand Multi-Asset Indexes
MSCI buys Compass Financial Technologies to strengthen multi-asset index capabilities spanning equities, commodities and digital assets while expanding its analytics reach.
Compass, Inc. (COMP) Q4 2025 Earnings Call Transcript
Compass, Inc. (COMP) Q4 2025 Earnings Call Transcript
Compass, Inc. (COMP) Reports Q4 Loss, Tops Revenue Estimates
Compass, Inc. (COMP) came out with a quarterly loss of $0.07 per share versus the Zacks Consensus Estimate of a loss of $0.06. This compares to a loss of $0.08 per share a year ago.
Compass, Inc. (COMP) Expected to Beat Earnings Estimates: Should You Buy?
Compass (COMP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot
Compass Pathways: Stock Soars As Data Sets Up Psilocybin Approval Shot
Compass Pathways' depression treatment meets main goal in late‑stage study
Drug developer Compass Pathways said on Tuesday its psilocybin-based depression therapy met the main goal in a late-stage study.
Is Compass Stock a Buy After Barrier Capital Initiated a Position Worth Over $10 Million?
Barrier Capital bought 952,074 shares of Compass; estimated trade value of $10.06 million based on quarterly average pricing. Quarter-end position value increased by $10.06 million, reflecting the new share acquisition.
CMPGY vs. BROS: Which Stock Is the Better Value Option?
Investors with an interest in Retail - Restaurants stocks have likely encountered both Compass Group PLC (CMPGY) and Dutch Bros (BROS). But which of these two stocks offers value investors a better bang for their buck right now?
Compass Group falls as guidance left unchanged
Compass Group PLC shares fell 7.7% to 2,050p on Thursday despite posting a trading update for what it called a strong start to the year and reaffirming its full-year guidance. The FTSE 100 catering group reporting 7.3% organic revenue growth for the first quarter, which was down from the 8.7% growth seen in the past full year.
Will Compass be an AI loser from lower office demand? UBS thinks not
The recent pullback in Compass Group PLC (LSE:CPG) shares is unjustified, according to UBS, which argues that the market's concerns around the potential impact of AI on employment and demand for workplace catering are overcooked. In a note to clients, the Swiss bank noted that some investors view the FTSE 100 group as an "AI loser", hit by second-order effects as job displacement in the wider economy leads to top-line pressure.
Compass Therapeutics: Exciting Clinical Updates Inbound For 2026
Compass Therapeutics remains a 'Buy,' but valuation above $1B stretches risk/reward as it awaits pivotal clinical catalysts. Tovecimig's early data in biliary tract and refractory colorectal cancers show promise, with key COMPANION-002 updates expected late Q1 2026. CMPX's cash runway extends into 2028, supporting continued clinical progress and mitigating near-term financing risk.
